Less than 10% of patients that would benefit from obesity jabs including Wegovy have access to them, caution the World Health Organization as it issues its inaugural guidance on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to GLP-1 medication.
Per forecasts, over two billion could be obese by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to widespread availability to the treatments that can assist patients in reducing significant weight, explains the agency.
GLP-1 Therapy Shortage
Even in the present most optimistic scenario, the production of GLP-1 therapies would only suffice for about 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation urges nations and manufacturers to widen access, through approaches including licensing agreements.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is set to lapse in multiple countries in 2026.
The Way Obesity Jabs Operate
These medications imitate a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people consume fewer calories.
Individuals typically see weight reduction in the initial weeks of commencing the once-weekly jabs.
Evidence points to patients may put most of the weight back on a year later of discontinuing the drug, because their normal hunger return.
To be above a healthy weight elevates your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the health agency.
